Columbia professor says PACE damaging Lancet’s reputation

Yesterday, Columbia University professor of statistics Andrew Gelman published a warning that The Lancet was risking its reputation by refusing to rectify errors in the main paper on the PACE trial that appeared in the journal in 2011.
In his article on a popular statistics blog, Professor Gelman described the PACE authors’ refusal to share data from the study as “unforgivable”. In a reference to the much-criticised “normal range” analyses that appeared in the Lancet paper, he said, “No paper with an analysis in which you can get worse and be counted as improved should ever be published.”
Professor Gelman said that despite this “absurd” analysis, PACE has been presented as “definitive” in  the scientific literature and by public health agencies. He said that he suspects that the trial has stood so long because “The Lancet’s brand name gave this paper a pass.”
He noted that although Lancet editor Richard Horton said that the paper had undergone “endless rounds of peer review”, it is flagged online as having been “fast-tracked”, a process that takes four weeks according to current Lancet policy.
Professor Gelman said that, regardless of whether the paper had been reviewed repeatedly or very little, typically “reviewers have neither access to the raw data nor the time for careful reanalysis” and that “mistakes are inevitable.” But, he said, “What I can’t excuse is the journal editor’s dogged defense of a flawed paper.”
He went on to argue that if a poor paper was allowed to hide behind a journal’s reputation then it was right that the journal’s reputation should be degraded. He said, “The Lancet editor is using his journal’s reputation to defend the controversial study. But, as the study becomes more and more disparaged, the sharing of reputation goes the other way.”
Professor Gelman described imagining a scientist in future saying, “The Lancet, eh? Isn’t that the journal that published the discredited Iraq survey, the Andrew Wakefield paper, and that weird PACE study?”
He concluded his article by saying, “Long run, reputation should catch up to reality. But before the long run comes, there are a few people out there with chronic fatigue syndrome who don’t feel like waiting.”
Professor Gelman recently published two other articles critical of PACE (here and here). He is one of a growing band of academics who have become interested in the shortcomings of the PACE trial since a series of critical blog posts by Dr. David Tuller, Professor James Coyne and others in recent months.
The PACE trial was a £5 million randomised trial whose authors claim that it showed that cognitive therapy and graded exercise are beneficial for chronic fatigue syndrome patients.

Facebook
Twitter
WhatsApp
Email

2 thoughts on “Columbia professor says PACE damaging Lancet’s reputation”

Comments are closed.

Latest News

#MEAction logo is in white in the top left corner and the words Colorado State Chapter are in white laying across an image of snow capped mountains and pine trees. There is a bottom section of the image that is a green box with the words Working-With-Governors-Office-to-Create A New Senior Policy Advisor Role-Leading to Statewide Report on Long COVID

#MEAction Colorado Works With Governor’s Office to Create A New Senior Policy Advisor Role on Long COVID and Post Viral Infection Planning–Leading to Statewide Report on Long COVID

#MEAction Colorado’s first legislative effort in Colorado began with an ME/CFS day declaration in the Colorado Legislature on February 25, 2020. Representative Alex Valdez read into the legislative record a proclamation about the presence of and deleterious effects of ME in Colorado. This effort was relatively easy to accomplish and consisted of finding a representative

Read More »
Left: Woman healthy and happy standing beside her husband. Right: Sick woman in hospital bed.

Woman with Severe ME and EDS starving to death in NHS hospital

UPDATE: We want to provide a brief update on Sami Berry’s case and what she needs help with now. The situation in hospital reached the point that Sami decided she had to self-discharge to try and stay alive. She is at home with a Percutaneous Endoscopic Jejunostomy (PEJ ) tube but she needs treatment with

Read More »

Help keep our work going

We rely on donations from people like you to keep fighting for equality for people with ME.

Donate

Get actions alerts and news direct to your inbox

You can choose what you want to be kept up to date on.

Subscribe
Scroll to Top